JP Morgan Maintains Overweight on Guardant Health, Raises Price Target to $135

Benzinga Newsdesk www.benzinga.com Positive 82.1%

Neg 0% Neu 0% Pos 82.1%

JP Morgan analyst Casey Woodring maintains Guardant Health (NASDAQ:GH) with a Overweight and raises the price target from $130 to $135.